{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:20:51Z","timestamp":1792200051597,"version":"4.4.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11897-019-00436-z","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T12:03:47Z","timestamp":1568376227000},"page":"180-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis"],"prefix":"10.1007","volume":"16","author":[{"given":"Deepa M.","family":"Gopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar K.","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,13]]},"reference":[{"issue":"4","key":"436_CR1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","volume":"25","author":"MD Benson","year":"2018","unstructured":"\u2022 Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, MJM S, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215\u20139 An important paper published in 2018 by the International Society of Amyloidosis nomenclature committee regarding updates and consensus recommendations for nomenclature regarding the various types amyloidosis.","journal-title":"Amyloid"},{"issue":"8","key":"436_CR2","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/archinte.1983.00350080055015","volume":"143","author":"CA Libbey","year":"1983","unstructured":"Libbey CA, Skinner M, Cohen AS. Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med. 1983;143(8):1549\u201352.","journal-title":"Arch Intern Med"},{"key":"436_CR3","first-page":"331","volume":"5","author":"J Robbins","year":"1976","unstructured":"Robbins J. Thyroxine-binding proteins. Prog Clin Biol Res. 1976;5:331\u201355.","journal-title":"Prog Clin Biol Res"},{"issue":"7","key":"436_CR4","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1742-4658.2007.05712.x","volume":"274","author":"X Hou","year":"2007","unstructured":"Hou X, Aguilar MI, Small DH. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J. 2007;274(7):1637\u201350.","journal-title":"FEBS J"},{"issue":"4","key":"436_CR5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mus.20821","volume":"36","author":"MD Benson","year":"2007","unstructured":"\u2022\u2022 Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36(4):411\u201323 A seminal paper reviewing the molecular and clinical features of ATTR variant disease and neuropathy.","journal-title":"Muscle Nerve"},{"key":"436_CR6","doi-asserted-by":"publisher","unstructured":"Aus dem Siepen F, Hein S, Prestel S, Baumgartner C, Schonland S, Hegenbart U, Rocken C, Katus HA, Kristen AV. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol. 2019 April 5. \n                      https:\/\/doi.org\/10.1007\/s00392-019-01467-1\n                      \n                    .","DOI":"10.1007\/s00392-019-01467-1"},{"issue":"10","key":"436_CR7","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","volume":"318","author":"HI Geller","year":"2017","unstructured":"Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. Jama. 2017;318(10):962\u20133.","journal-title":"Jama."},{"issue":"7","key":"436_CR8","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.62.7.1057","volume":"62","author":"Y Ando","year":"2005","unstructured":"Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62(7):1057\u201362.","journal-title":"Arch Neurol"},{"issue":"1\u20132","key":"436_CR9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jns.2014.06.041","volume":"344","author":"N Suanprasert","year":"2014","unstructured":"Suanprasert N, Berk JL, Benson MD, Dyck PJ, Klein CJ, Gollob JA, et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. J Neurol Sci. 2014;344(1\u20132):121\u20138.","journal-title":"J Neurol Sci"},{"issue":"2","key":"436_CR10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10286-018-0514-2","volume":"29","author":"A Gonzalez-Duarte","year":"2019","unstructured":"Gonzalez-Duarte A. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Clin Auton Res. 2019;29(2):245\u201351.","journal-title":"Clin Auton Res"},{"issue":"3","key":"436_CR11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.nmd.2004.10.015","volume":"15","author":"G Vita","year":"2005","unstructured":"Vita G, Mazzeo A, Di Leo R, Ferlini A. Recurrent syncope as persistently isolated feature of transthyretin amyloidotic polyneuropathy. Neuromuscul Disord. 2005;15(3):259\u201361.","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"436_CR12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.5692\/clinicalneurol.cn-000911","volume":"56","author":"T Uehara","year":"2016","unstructured":"Uehara T, Kakuda K, Sumi-Akamaru H, Yamauchi A, Mochizuki H, Naka T. An autopsy case of leptomeningeal amyloidosis associated with transthyretin Gly47Arg mutation. Rinsho Shinkeigaku. 2016;56(11):777\u201380.","journal-title":"Rinsho Shinkeigaku"},{"issue":"2","key":"436_CR13","first-page":"361","volume":"148","author":"R Vidal","year":"1996","unstructured":"Vidal R, Garzuly F, Budka H, Lalowski M, Linke RP, Brittig F, et al. Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G). Am J Pathol. 1996;148(2):361\u20136.","journal-title":"Am J Pathol"},{"issue":"1","key":"436_CR14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s00415-014-7594-2","volume":"262","author":"P McColgan","year":"2015","unstructured":"McColgan P, Viegas S, Gandhi S, Bull K, Tudor R, Sheikh F, et al. Oculoleptomeningeal amyloidosis associated with transthyretin Leu12Pro in an African patient. J Neurol. 2015;262(1):228\u201334.","journal-title":"J Neurol"},{"issue":"3","key":"436_CR15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ana.410410305","volume":"41","author":"RB Petersen","year":"1997","unstructured":"Petersen RB, Goren H, Cohen M, Richardson SL, Tresser N, Lynn A, et al. Transthyretin amyloidosis: a new mutation associated with dementia. Ann Neurol. 1997;41(3):307\u201313.","journal-title":"Ann Neurol"},{"issue":"10","key":"436_CR16","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1212\/01.WNL.0000065901.18353.AB","volume":"60","author":"G Blevins","year":"2003","unstructured":"Blevins G, Macaulay R, Harder S, Fladeland D, Yamashita T, Yazaki M, et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology. 2003;60(10):1625\u201330.","journal-title":"Neurology."},{"issue":"3","key":"436_CR17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506120308998998","volume":"10","author":"LH Connors","year":"2003","unstructured":"Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10(3):160\u201384.","journal-title":"Amyloid"},{"issue":"4","key":"436_CR18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/13506120209114104","volume":"9","author":"M Yazaki","year":"2002","unstructured":"Yazaki M, Connors LH, Eagle RC Jr, Leff SR, Skinner M, Benson MD. Transthyretin amyloidosis associated with a novel variant (Trp41Leu) presenting with vitreous opacities. Amyloid. 2002;9(4):263\u20137.","journal-title":"Amyloid"},{"issue":"1","key":"436_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/13506120410001673884","volume":"11","author":"L Lobato","year":"2004","unstructured":"Lobato L, Beirao I, Silva M, Fonseca I, Queiros J, Rocha G, et al. End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. Amyloid. 2004;11(1):27\u201337.","journal-title":"Amyloid"},{"issue":"12","key":"436_CR20","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jcmg.2018.06.010","volume":"11","author":"F Duca","year":"2018","unstructured":"Duca F, Kammerlander AA, Panzenbock A, Binder C, Aschauer S, Loewe C, et al. Cardiac magnetic resonance T1 mapping in cardiac amyloidosis. J Am Coll Cardiol Img. 2018;11(12):1924\u20136.","journal-title":"J Am Coll Cardiol Img"},{"issue":"2","key":"436_CR21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","volume":"111","author":"AM Maceira","year":"2005","unstructured":"Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186\u201393.","journal-title":"Circulation."},{"issue":"10","key":"436_CR22","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.echo.2007.02.025","volume":"20","author":"D Bellavia","year":"2007","unstructured":"Bellavia D, Abraham TP, Pellikka PA, Al-Zahrani GB, Dispenzieri A, Oh JK, et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr. 2007;20(10):1194\u2013202.","journal-title":"J Am Soc Echocardiogr"},{"issue":"9","key":"436_CR23","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/echo.13278","volume":"33","author":"V Schiano-Lomoriello","year":"2016","unstructured":"Schiano-Lomoriello V, Galderisi M, Mele D, Esposito R, Cerciello G, Buonauro A, et al. Longitudinal strain of left ventricular basal segments and E\/e\u2019 ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study. Echocardiography. 2016;33(9):1335\u201343.","journal-title":"Echocardiography"},{"issue":"1","key":"436_CR24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9149(82)90270-3","volume":"49","author":"JD Carroll","year":"1982","unstructured":"Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage\/mass relation. Am J Cardiol. 1982;49(1):9\u201313.","journal-title":"Am J Cardiol"},{"issue":"5","key":"436_CR25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","volume":"5","author":"YY Mints","year":"2018","unstructured":"Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail. 2018;5(5):772\u20139.","journal-title":"ESC Heart Fail"},{"issue":"5","key":"436_CR26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/hrt.74.5.541","volume":"74","author":"S Dubrey","year":"1995","unstructured":"Dubrey S, Pollak A, Skinner M, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J. 1995;74(5):541\u20134.","journal-title":"Br Heart J"},{"issue":"21","key":"436_CR27","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","volume":"116","author":"D Feng","year":"2007","unstructured":"Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116(21):2420\u20136.","journal-title":"Circulation."},{"issue":"2","key":"436_CR28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","volume":"13","author":"CR Barbhaiya","year":"2016","unstructured":"Barbhaiya CR, Kumar S, Baldinger SH, Michaud GF, Stevenson WG, Falk R, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016;13(2):383\u201390.","journal-title":"Heart Rhythm"},{"issue":"1","key":"436_CR29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1378\/chest.96.1.80","volume":"96","author":"N Anzai","year":"1989","unstructured":"Anzai N, Akiyama K, Tsuchida K, Yamada M, Kito S, Yamamura Y. Treatment by pacemaker in familial amyloid polyneuropathy. Chest. 1989;96(1):80\u20134.","journal-title":"Chest."},{"issue":"2","key":"436_CR30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10840-019-00517-y","volume":"55","author":"James Milner","year":"2019","unstructured":"Milner J, Teixeira RN, Marinho AV, Silva N, Calretas S, Ferrao J, Furtado E, Telo MJ, Ventura M, Cristovao J, Elvas L, Pego GM, Antonia N. Pacemaker implantation in familial amyloid polyneuropathy: when and for whom? J Interv Card Electrophysiol. 2019;55(2):207\u2013211.","journal-title":"Journal of Interventional Cardiac Electrophysiology"},{"key":"436_CR31","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","volume":"222","author":"D Hamon","year":"2016","unstructured":"Hamon D, Algalarrondo V, Gandjbakhch E, Extramiana F, Marijon E, Elbaz N, et al. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. Int J Cardiol. 2016;222:562\u20138.","journal-title":"Int J Cardiol"},{"issue":"6","key":"436_CR32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","volume":"24","author":"JJ Maleszewski","year":"2015","unstructured":"Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24(6):343\u201350.","journal-title":"Cardiovasc Pathol"},{"issue":"2","key":"436_CR33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10554-019-01570-4","volume":"35","author":"L Lehmonen","year":"2019","unstructured":"Lehmonen L, Kaasalainen T, Atula S, Mustonen T, Holmstrom M. Myocardial tissue characterization in patients with hereditary gelsolin (AGel) amyloidosis using novel cardiovascular magnetic resonance techniques. Int J Cardiovasc Imaging. 2019;35(2):351\u20138.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"6","key":"436_CR34","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"436_CR35","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00259-001-0730-0","volume":"29","author":"M Puille","year":"2002","unstructured":"Puille M, Altland K, Linke RP, Steen-Muller MK, Kiett R, Steiner D, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging. 2002;29(3):376\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"436_CR36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"\u2022\u2022 Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195\u2013201 This is the first article depicting the use of Tc-pyrophosphate scanning specifically for differentiating between light-chain and ATTR cardiac amyloidosis with incorporation of the heart-to-contralateral ratio.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"24","key":"436_CR37","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312.","journal-title":"Circulation."},{"issue":"11","key":"436_CR38","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","volume":"45","author":"G Treglia","year":"2018","unstructured":"Treglia G, Glaudemans A, Bertagna F, Hazenberg BPC, Erba PA, Giubbini R, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging. 2018;45(11):1945\u201355.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10038","key":"436_CR39","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"\u2022\u2022 Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641\u201354 This is a very comprehensive and up-to-date-review of systemic amyloidosis and the various clinical treatments and outcomes associated with each type of amyloidosis.","journal-title":"Lancet"},{"issue":"22","key":"436_CR40","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"\u2022\u2022 Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872\u201391 A very recent review of ATTR cardiac amyloidosis reviewing pathophysiology, diagnosis, management, and clinical treatment algorithms for ATTR disease.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"436_CR41","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","volume":"87","author":"P Westermark","year":"1990","unstructured":"Westermark P, Sletten K, Johansson B, Cornwell GG 3rd. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990;87(7):2843\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"436_CR42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/BF02190707","volume":"86","author":"MR Almeida","year":"1991","unstructured":"Almeida MR, Hesse A, Steinmetz A, Maisch B, Altland K, Linke RP, et al. Transthyretin Leu 68 in a form of cardiac amyloidosis. Basic Res Cardiol. 1991;86(6):567\u201371.","journal-title":"Basic Res Cardiol"},{"issue":"7","key":"436_CR43","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","volume":"19","author":"JN Buxbaum","year":"2017","unstructured":"\u2022 Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017;19(7):733\u201342 A comprehensive assessment of ATTRV122I cardiac amyloidosis disussing the available data on genetic penetrance, prevalence, and outcomes seen in this specific and most frequent ATTR genetic mutation seen in the United States.","journal-title":"Genet Med"},{"issue":"1","key":"436_CR44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(92)90672-X","volume":"93","author":"I Ranlov","year":"1992","unstructured":"Ranlov I, Alves IL, Ranlov PJ, Husby G, Costa PP, Saraiva MJ. A Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretin-methionine111 variant in serum from patients and carriers. Am J Med. 1992;93(1):3\u20138.","journal-title":"Am J Med"},{"issue":"9","key":"436_CR45","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","volume":"33","author":"PT Sattianayagam","year":"2012","unstructured":"Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33(9):1120\u20137.","journal-title":"Eur Heart J"},{"issue":"2","key":"436_CR46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"\u2022 Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161\u201372 Utilizing an international registry of ATTR amyloidosis, this study describes the genotype and phenotype of ATTR cardiomyopathy in the US with comparison to the rest of the world.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"436_CR47","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ahj.2009.08.006","volume":"158","author":"LH Connors","year":"2009","unstructured":"Connors LH, Prokaeva T, Lim A, Theberge R, Falk RH, Doros G, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009;158(4):607\u201314.","journal-title":"Am Heart J"},{"issue":"3","key":"436_CR48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","volume":"22","author":"DR Jacobson","year":"2015","unstructured":"Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22(3):171\u20134.","journal-title":"Amyloid"},{"issue":"3","key":"436_CR49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506120802193720","volume":"15","author":"U Hellman","year":"2008","unstructured":"Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 2008;15(3):181\u20136.","journal-title":"Amyloid."},{"issue":"7","key":"436_CR50","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","volume":"7","author":"C Rapezzi","year":"2010","unstructured":"Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398\u2013408.","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"436_CR51","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1136\/jmg.40.11.e120","volume":"40","author":"V Plante-Bordeneuve","year":"2003","unstructured":"Plante-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet. 2003;40(11):e120.","journal-title":"J Med Genet"},{"issue":"7","key":"436_CR52","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1212\/WNL.58.7.1001","volume":"58","author":"S Ikeda","year":"2002","unstructured":"Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology. 2002;58(7):1001\u20137.","journal-title":"Neurology."},{"issue":"Pt 10","key":"436_CR53","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/brain\/122.10.1951","volume":"122","author":"K Misu","year":"1999","unstructured":"Misu K, Hattori N, Nagamatsu M, Ikeda S, Ando Y, Nakazato M, et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain. 1999;122(Pt 10):1951\u201362.","journal-title":"Brain."},{"issue":"1","key":"436_CR54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/13506120701815373","volume":"15","author":"C Rapezzi","year":"2008","unstructured":"Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S, et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid. 2008;15(1):40\u20138.","journal-title":"Amyloid."},{"issue":"2","key":"436_CR55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1399-0004.2008.01097.x","volume":"75","author":"M Olsson","year":"2009","unstructured":"Olsson M, Hellman U, Plante-Bordeneuve V, Jonasson J, Lang K, Suhr OB. Mitochondrial haplogroup is associated with the phenotype of familial amyloidosis with polyneuropathy in Swedish and French patients. Clin Genet. 2009;75(2):163\u20138.","journal-title":"Clin Genet"},{"issue":"2","key":"436_CR56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/path.2411","volume":"216","author":"E Ihse","year":"2008","unstructured":"Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol. 2008;216(2):253\u201361.","journal-title":"J Pathol"},{"issue":"3","key":"436_CR57","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/13506129.2013.797890","volume":"20","author":"E Ihse","year":"2013","unstructured":"Ihse E, Rapezzi C, Merlini G, Benson MD, Ando Y, Suhr OB, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid. 2013;20(3):142\u201350.","journal-title":"Amyloid."},{"issue":"2","key":"436_CR58","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/path.1759","volume":"206","author":"J Bergstrom","year":"2005","unstructured":"Bergstrom J, Gustavsson A, Hellman U, Sletten K, Murphy CL, Weiss DT, et al. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol. 2005;206(2):224\u201332.","journal-title":"J Pathol"},{"issue":"1","key":"436_CR59","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mus.20644","volume":"35","author":"I Conceicao","year":"2007","unstructured":"Conceicao I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve. 2007;35(1):116\u20138.","journal-title":"Muscle Nerve"},{"issue":"1","key":"436_CR60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/13506120009146826","volume":"7","author":"LH Connors","year":"2000","unstructured":"Connors LH, Richardson AM, Theberge R, Costello CE. Tabulation of transthyretin (TTR) variants as of 1\/1\/2000. Amyloid. 2000;7(1):54\u201369.","journal-title":"Amyloid."},{"issue":"3","key":"436_CR61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2796.2003.01173.x","volume":"254","author":"OB Suhr","year":"2003","unstructured":"Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranlov PJ. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med. 2003;254(3):225\u201335.","journal-title":"J Intern Med"},{"issue":"1","key":"436_CR62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","volume":"26","author":"I Conceicao","year":"2019","unstructured":"Conceicao I, Damy T, Romero M, Galan L, Attarian S, Luigetti M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019;26(1):3\u20139.","journal-title":"Amyloid."},{"issue":"Suppl 1","key":"436_CR63","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","volume":"29","author":"L Obici","year":"2016","unstructured":"Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29(Suppl 1):S27\u201335.","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"436_CR64","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mus.25210","volume":"54","author":"HH Schmidt","year":"2016","unstructured":"Schmidt HH, Barroso F, Gonzalez-Duarte A, Conceicao I, Obici L, Keohane D, et al. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2016;54(3):353\u201360.","journal-title":"Muscle Nerve"},{"issue":"13 Pt 1","key":"436_CR65","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/0002-9149(85)90996-8","volume":"55","author":"MA Gertz","year":"1985","unstructured":"Gertz MA, Skinner M, Connors LH, Falk RH, Cohen AS, Kyle RA. Selective binding of nifedipine to amyloid fibrils. Am J Cardiol. 1985;55(13 Pt 1):1646.","journal-title":"Am J Cardiol"},{"issue":"13 Pt 1","key":"436_CR66","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","volume":"55","author":"MA Gertz","year":"1985","unstructured":"Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985;55(13 Pt 1):1645.","journal-title":"Am J Cardiol"},{"issue":"2","key":"436_CR67","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","volume":"25","author":"E Muchtar","year":"2018","unstructured":"Muchtar E, Gertz MA, Kumar SK, Lin G, Boilson B, Clavell A, et al. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use. Amyloid. 2018;25(2):86\u201392.","journal-title":"Amyloid"},{"issue":"3","key":"436_CR68","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","volume":"40","author":"G Holmgren","year":"1991","unstructured":"Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991;40(3):242\u20136.","journal-title":"Clin Genet"},{"issue":"8853","key":"436_CR69","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","volume":"341","author":"G Holmgren","year":"1993","unstructured":"Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341(8853):1113\u20136.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"436_CR70","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/13506129.2011.574354072","volume":"18","author":"HE Wilczek","year":"2011","unstructured":"Wilczek HE, Larsson M, Ericzon BG. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid. 2011;18(Suppl 1):193\u20135.","journal-title":"Amyloid"},{"issue":"4","key":"436_CR71","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/13506129.2011.615872","volume":"18","author":"S Okamoto","year":"2011","unstructured":"Okamoto S, Zhao Y, Lindqvist P, Backman C, Ericzon BG, Wijayatunga P, et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid. 2011;18(4):200\u20135.","journal-title":"Amyloid"},{"issue":"10","key":"436_CR72","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/TP.0b013e31824b3749","volume":"93","author":"S Gustafsson","year":"2012","unstructured":"Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation. 2012;93(10):1017\u201323.","journal-title":"Transplantation."},{"issue":"1","key":"436_CR73","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00007890-199707150-00014","volume":"64","author":"SW Dubrey","year":"1997","unstructured":"Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation. 1997;64(1):74\u201380.","journal-title":"Transplantation."},{"issue":"3","key":"436_CR74","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/lt.500050309","volume":"5","author":"A Garcia-Herola","year":"1999","unstructured":"Garcia-Herola A, Prieto M, Pascual S, Berenguer M, Lopez-Viedma B, Mir J, et al. Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant. Liver Transpl Surg. 1999;5(3):246\u20138.","journal-title":"Liver Transpl Surg"},{"key":"436_CR75","unstructured":"Coelho T, Carvalho M, Saraiva MJ, Alves I, Almeida MR, Costa PP. A strikingly benign evolution of FAP in an individual compound heterozygote for two TTR mutations: TTR Met30 and TTR Met119. J Rheumatol. 1993;20:179."},{"issue":"5539","key":"436_CR76","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","volume":"293","author":"P Hammarstrom","year":"2001","unstructured":"Hammarstrom P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293(5539):2459\u201362.","journal-title":"Science"},{"issue":"8","key":"436_CR77","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"\u2022\u2022 Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785\u201392 A randomized-controlled trial of 128 patients with ATTRv neuropathy randomized to tafamadis (TTR stabilizer) or placebo which did not meet primary end-point of trial but in secondary analyses showed significant delay in neurologic impairment.","journal-title":"Neurology"},{"issue":"21","key":"436_CR78","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","volume":"91","author":"T Coelho","year":"2018","unstructured":"Coelho T, Ines M, Conceicao I, Soares M, de Carvalho M, Costa J. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology. 2018;91(21):e1999\u20132009.","journal-title":"Neurology."},{"issue":"24","key":"436_CR79","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"\u2022\u2022 Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. Jama. 2013;310(24):2658\u201367 The randomized-controlled trial of 130 patients with ATTRv polyneuropathy randomized to diflunisal or placebo showing efficacy of diflunisal in reducing neurologic progression and preserving quality of life at 2 years.","journal-title":"Jama"},{"issue":"4","key":"436_CR80","doi-asserted-by":"crossref","first-page":"e004769","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","volume":"11","author":"H Rosenblum","year":"2018","unstructured":"Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS. TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis. Circ Heart Fail. 2018;11(4):e004769.","journal-title":"Circ Heart Fail"},{"issue":"11","key":"436_CR81","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"\u2022\u2022 Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316 A recent randomized-controlled trial evaluating tafamadis vs. placebo in ATTR cardiac amyloidosis resulting in reduced all-cause mortality and cardiovascular-related hospitalizations in tafamadis treated patients, particularly in ATTRwt and NYHA I-II patients.","journal-title":"N Engl J Med"},{"issue":"1","key":"436_CR82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"\u2022\u2022 Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321 This phase 3 randomized-controlled trial evaluated intravenous patisiran vs. placebo in ATTR amyloidosis with polyneuropathy showed statistically significant improvements in multiple neurologic clinical metrics in patisiran-treated arm compared to placebo.","journal-title":"N Engl J Med"},{"issue":"4","key":"436_CR83","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, et al. Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139(4):431\u201343.","journal-title":"Circulation."},{"issue":"11","key":"436_CR84","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"\u2022\u2022 Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotereson treatment for patients with hereditary transthyretic amyloidosis. N Engl J Med. 2018;379(11):22\u201331 This phase 3 randomized-controlled trial evaluated subcutaneous inotersen vs. placebo in ATTR amyloidosis with polyneuropathy showing improved course of neurologic disease in patients treated with inotersen compared to placebo controls.","journal-title":"N Engl J Med"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-019-00436-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-019-00436-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-019-00436-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T19:21:44Z","timestamp":1599852104000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-019-00436-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,13]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1007\/s11897-019-00436-z","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,13]]},"assertion":[{"value":"13 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Ruberg and Dr. Gopal receive research funding from Eidos Therapeutics. Dr. Ruberg receives research and consulting income from Pfizer. Dr. Siddiqi has no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}